section name header

Evidence summaries

Sotalol after Myocardial Infarction

Sotalol increases mortality in patients with myocardial infarction and left ventricular dysfunction. Level of evidence: "A"

A topic in Clinical Evidence 1 summarizes the evidence on sotalol in patients with myocardial infarction. One RCT (3 121 patients) included patients with left ventricular dysfunction. Sotalol increased mortality (AR for death 5% vs 3.1%, RR 1.65, 95% CI 1.15 to 2.36). The trial was terminated prematurely after less than 1 year.

The following decision support rules contain links to this evidence summary:

References

Primary/Secondary Keywords